Danielle Land
Family · Philadelphia, PANPI 1730411786
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $42,598 of the $48,044 with a category attached, or 88.7%. 6 manufacturers reported payments, led by Beigene USA, Inc. at 31.2% of the total. Reporting peaked in 2021 at $22,190 and has fallen 86.1% since, to $3,086 in 2025. Among family clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 75 payments — averaging $640.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Beigene USA, Inc.$15K
- Johnson & Johnson$12K
- AstraZeneca$12K
- Pharmacyclics LLC, An Abbvie Company$9K
- Incyte Corporation$1K
- Gilead$37
What the payments were for
- Consulting fees$3,1156%
- Speaking & faculty fees$42,59889%
- Travel & lodging$1,7674%
- Food & beverage$5651%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Beigene USA, Inc. | 21 | $14,978 |
| Johnson & Johnson | 17 | $11,561 |
| AstraZeneca | 23 | $11,556 |
| Pharmacyclics LLC, An Abbvie Company | 11 | $8,862 |
| Incyte Corporation | 1 | $1,050 |
| Gilead | 2 | $37 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$48,044 in reported general payments places this provider in the 95th percentile of 4,717 family providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CalquenceAcalabrutinib Maleate | 295 | $3,309,631 |
| ImbruvicaIbrutinib | 156 | $1,811,726 |
| JaypircaPirtobrutinib | 50 | $915,334 |
| BrukinsaZanubrutinib | 91 | $836,399 |
| VenclextaVenetoclax | 72 | $321,289 |
| CopiktraDuvelisib | 11 | $261,258 |
| Lenalidomide | 16 | $247,695 |
| EliquisApixaban | 11 | $6,451 |
| ValacyclovirValacyclovir Hcl | 105 | $5,848 |
| ProzacFluoxetine Hcl | 12 | $4,996 |
| Potassium Chloride | 19 | $1,183 |
| Acyclovir | 42 | $1,069 |
| Pantoprazole Sodium | 20 | $231 |
| Azithromycin | 26 | $210 |
| Gabapentin | 28 | $210 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaCalquence | $11,556 | $3,309,631295 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $8,862 | $1,811,726156 claims |
| Beigene USA, Inc.Brukinsa | $14,978 | $836,39991 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,717 family providers in Pennsylvania.
Other family in Philadelphia
- Bethany ThomasPhiladelphia$126K
- Anne CalvaresiPhiladelphia$81K
- Bethany MooneyPhiladelphia$73K
- Susan Estrella-EadesPhiladelphia$61K
- Michelle Vega-OlivoPhiladelphia$55K
- Nicole SmithPhiladelphia$37K
- Dana SerafinPhiladelphia$31K
- Tammaris KaschakPhiladelphia$27K
- Laura NoltePhiladelphia$21K
- Christopher RenziPhiladelphia$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.